<div id="readability-page-1"><p>Allspring Global Investments Holdings LLC cut its position in  Enovis Corporation (NYSE:ENOV - Free Report) by 16.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 679,176 shares of the company's stock after selling 131,595 shares during the quarter. Allspring Global Investments Holdings LLC owned about 1.19% of Enovis worth $20,688,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><p>Several other large investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC increased its holdings in shares of  Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company's stock worth $37,000 after purchasing an additional 367 shares during the period.  EverSource Wealth Advisors LLC grew its position in  Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock worth $40,000 after buying an additional 707 shares in the last quarter.  Elevation Point Wealth Partners LLC bought a new position in  Enovis in the 2nd quarter worth about $46,000.  CWM LLC raised its holdings in shares of  Enovis by 564.9% in the 2nd quarter. CWM LLC now owns 3,790 shares of the company's stock valued at $119,000 after acquiring an additional 3,220 shares in the last quarter.  Finally, Tower Research Capital LLC TRC boosted its position in shares of  Enovis by 578.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,347 shares of the company's stock valued at $136,000 after acquiring an additional 3,706 shares during the last quarter. 98.45% of the stock is owned by institutional investors. </p><h2>Insider Activity at Enovis</h2><p>In other Enovis news, EVP Daniel A. Pryor sold 999 shares of Enovis stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider John Kleckner acquired 2,468 shares of the stock in a transaction on Tuesday, November 25th. The stock was bought at an average price of $30.32 per share, with a total value of $74,829.76. Following the transaction, the insider directly owned 12,302 shares of the company's stock, valued at approximately $372,996.64. The trade was a 25.10% increase in their position. The disclosure for this purchase is available in the SEC filing. 2.70% of the stock is owned by company insiders. </p><h2>Analyst Upgrades and Downgrades</h2><p>ENOV has been the topic of a number of recent analyst reports. Canaccord Genuity Group lowered their target price on shares of Enovis from $58.00 to $50.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, December 17th. Wells Fargo &amp; Company increased their price target on shares of Enovis from $41.00 to $42.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, November 7th. Finally, Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Enovis in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the stock. According to data from MarketBeat, Enovis presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $49.83.</p><p><b>Check Out Our Latest Analysis on Enovis</b></p><h2>Enovis Price Performance</h2><p>Shares of NYSE:ENOV opened at $26.44 on Friday. The company has a quick ratio of 1.16, a current ratio of 2.22 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.51 billion, a PE ratio of -1.12 and a beta of 1.52. The company's fifty day moving average is $28.72 and its 200 day moving average is $29.98. Enovis Corporation has a 52 week low of $25.47 and a 52 week high of $49.38. </p><p>Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. The firm had revenue of $383.81 million for the quarter. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%. Research analysts anticipate that  Enovis Corporation will post 2.79 earnings per share for the current year. </p><h2>Enovis Company Profile</h2> (Free Report)<p>Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation. </p><p>The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Enovis</li><li>A month before the crash</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>The Last Gold Bull Market </li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li></ul><p><strong>Want to see what other hedge funds are holding ENOV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVOT1Y?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVOT1Y"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Enovis Right Now?</h2><p>Before you consider Enovis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.</p><p>While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ENOV

<p>Allspring Global Investments Holdings LLC reduced its stake in Enovis Corporation (NYSE:ENOV) by 16.2% in Q3, now holding 679,176 shares valued at approximately $20.7 million. Other investors, including Farther Finance Advisors and CWM LLC, have also adjusted their positions. Analyst ratings for Enovis vary, with a consensus rating of "Moderate Buy" and an average target price of $49.83. Enovis shares opened at $26.44, with a market cap of $1.51 billion and a PE ratio of -1.12. The company reported $0.59 EPS for the last quarter.</p>

Allspring Global Investments Holdings LLC Trims Stock Position in Enovis Corporation $ENOV